Literature DB >> 7816518

Prenatal diagnosis of collagen disorders by direct biochemical analysis of chorionic villus biopsies.

M Raghunath1, B Steinmann, C Delozier-Blanchet, P Extermann, A Superti-Furga.   

Abstract

We have developed a method for early prenatal diagnosis of molecular disorders of collagens I and III. The method takes advantage of the fact that isolated chorionic villi contain significant amounts of collagens in their extracellular matrix (stroma) and that they synthesize collagens in vitro. After metabolic labeling of chorion villus biopsies in toto with radioactive amino acids, collagens are extracted and analyzed by SDS-PAGE. Direct staining of the gel shows collagens synthesized in vivo, whereas autoradiofluorography identifies collagens synthesized during incubation in vitro. Unlike collagens synthesized by cultured amniotic fluid cells, collagens extracted from chorionic villi are not overmodified and thus allow better identification of molecular defects. Results are available within 3 to 5 d after biopsy. Using this method, we have correctly excluded Ehlers-Danlos syndrome type IV in two pregnancies, Ehlers-Danlos syndrome type VII in one pregnancy, and lethal osteogenesis imperfecta in four pregnancies. In addition, we correctly predicted a healthy fetus and an embryo affected with lethal osteogenesis imperfecta in consecutive pregnancies from a couple in which the asymptomatic mother was a somatic mosaic for a COL1A1 G-to-A transition (Gly355Asp). Direct collagen analysis of chorion villus biopsies labeled in toto is rapid and reliable and may become the method of choice for the prenatal diagnosis of selected collagen disorders.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7816518     DOI: 10.1203/00006450-199410000-00005

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  8 in total

1.  Technique to accurately quantify collagen content in hyperconfluent cell culture.

Authors:  Eugene Yong-Shun See; Siew Lok Toh; James Cho Hong Goh
Journal:  J Mol Histol       Date:  2008-11-08       Impact factor: 2.611

2.  The Scar-in-a-Jar: studying potential antifibrotic compounds from the epigenetic to extracellular level in a single well.

Authors:  C Z C Chen; Y X Peng; Z B Wang; P V Fish; J L Kaar; R R Koepsel; A J Russell; R R Lareu; M Raghunath
Journal:  Br J Pharmacol       Date:  2009-09-28       Impact factor: 8.739

3.  Evidence for a de novo, dominant germ-line mutation causative of osteogenesis imperfecta in two Red Angus calves.

Authors:  Jessica L Petersen; Shauna M Tietze; Rachel M Burrack; David J Steffen
Journal:  Mamm Genome       Date:  2019-02-20       Impact factor: 2.957

4.  Genetic counselling on brittle grounds: recurring osteogenesis imperfecta due to parental mosaicism for a dominant mutation.

Authors:  M Raghunath; K Mackay; R Dalgleish; B Steinmann
Journal:  Eur J Pediatr       Date:  1995-02       Impact factor: 3.183

5.  Novel use for polyvinylpyrrolidone as a macromolecular crowder for enhanced extracellular matrix deposition and cell proliferation.

Authors:  Rafi Rashid; Natalie Sheng Jie Lim; Stella Min Ling Chee; Si Ning Png; Thorsten Wohland; Michael Raghunath
Journal:  Tissue Eng Part C Methods       Date:  2014-05-02       Impact factor: 3.056

6.  Focus on collagen: in vitro systems to study fibrogenesis and antifibrosis state of the art.

Authors:  Clarice Zc Chen; Michael Raghunath
Journal:  Fibrogenesis Tissue Repair       Date:  2009-12-15

7.  Cellular re- and de-programming by microenvironmental memory: why short TGF-β1 pulses can have long effects.

Authors:  Ariel Bing-Shi Tan; Sebastian Kress; Leticia Castro; Allan Sheppard; Michael Raghunath
Journal:  Fibrogenesis Tissue Repair       Date:  2013-06-19

Review 8.  Reproductive options for families at risk of Osteogenesis Imperfecta: a review.

Authors:  Lidiia Zhytnik; Kadri Simm; Andres Salumets; Maire Peters; Aare Märtson; Katre Maasalu
Journal:  Orphanet J Rare Dis       Date:  2020-05-27       Impact factor: 4.123

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.